Overview

Novel Cognitive Treatment Targets for Epidiolex in Sturge- Weber Syndrome

Status:
Recruiting
Trial end date:
2021-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to better understand the utility of cannabidiol (CBD/ Epidiolex) for improving the treatment of cognitive impairments in Sturge-Weber syndrome (SWS).
Phase:
Phase 2
Details
Lead Sponsor:
Anne Comi, MD
Collaborators:
Faneca 66 Foundation
GW Pharmaceuticals Ltd.
Treatments:
Cannabidiol
Epidiolex